Fabrication of biodegradable poly(d,l-lactide-co-glycolide) nanoparticles containing tamoxifen citrate

Iranian Polymer Journal (English Edition)

Volumn 19, Issue 6, 2010, Pages 437-446

  Mirzajani, Fatemeh ^a   Rafati, Hasan ^a   Atyabi, Fatemeh ^b  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti cancer; Factorial design; Nanoparticle; PLGA; Tamoxifen citrate

Indexed keywords

ANTI-CANCER; ANTI-CANCER THERAPIES; ANTICANCER DRUG; AQUEOUS SOLUBILITY; DELIVERY SYSTEMS; DRUG CONTENT; DRUG LOADING; FACTORIAL DESIGN; FULL FACTORIAL; IN-VIVO; INDEPENDENT VARIABLES; LOADING CAPACITIES; MEAN SIZE; NANOCARRIERS; OIL/WATER; OPTIMIZATION STUDIES; OPTIMIZED CONDITIONS; OPTIMUM FORMULATION; ORGANIC PHASE; PLGA; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); PRODUCTION CONDITION; SEM; SIDE EFFECT; SOLVENT EVAPORATION METHOD; TAMOXIFEN; TAMOXIFEN CITRATE;

BIODEGRADABLE POLYMERS; CONTROLLED DRUG DELIVERY; DESIGN; DRUG INTERACTIONS; DYNAMIC LIGHT SCATTERING; EMULSIFICATION; OPTIMIZATION; ORGANIC POLYMERS; SCANNING ELECTRON MICROSCOPY;

NANOPARTICLES;

EID: 77955684808     PISSN: 10261265     EISSN: 10261265     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sosnik A, Chiappetta DA, Carcaboso AM, Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead, J Control Rel, 138, 2-15, 2009.
2. Fu Y, Kao WJ, Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems, Exp Opin on Drug Deliv, 7, 429-444, 2010.
3. Sahoo SK, Panyam J, Prabha S, Labhasetwar V, Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake, J Control Rel, 82, 105-114, 2002.
4. Lu JM, Wang XW, Marin-Muller C, Wang H, Lin PH, Yao QZ, Chen CY, Current advances in research and clinical applications of PLGA-based nanotechnology, Exp Rev Mol Diag, 9, 325-341, 2009.
5. Hans L, Lowman AM, Biodegradable nanoparti-cles for drug delivery and targeting, Curr Opin Solid State Mater Sci, 6, 319-327, 2002.
6. Mohammadi Y, Mirzadeh H, Moztarzadeh F, Soleimani M, Jabbari E, Osteogenic differentiation of mesenchymal stem cells on novel three-dimensional poly(L-lactic acid)/chitosan/gelatin/E-tricalcium phosphate hybrid scaffolds, Iran Polym J, 16, 57-69, 2007.
7. World Health Organization, Statistics, http://www.who.int/features/qa/15/ en/, Available in 1st April, 2008.
8. National Cancer Institute, Breast cancer, http://www.cancer.gov/ cancertopics/types/breast/, 2008.
9. Grillo-Lopez AJ, Cancer therapies crisis in the USA, Expert Rev Anticancer Ther, 3, 579-582, 2003.
10. Moses MA, Brem H, Langer R, Advancing the field of drug delivery: taking aim at cancer, Canc Cell, 4, 337-341, 2003.
11. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R, Lipid-based nano-particles as pharmaceutical drug carriers: from concepts to clinic, Crit Rev Therap Drug Carr Sys, 26, 523-580, 2009.
12. Mobedi H, Nekoomanesh M, Orafaei H, Mivechi H, Studying the degradation of poly(L-lactide) in presence of magnesium hydroxide, Iran Polym J, 15, 31-39, 2006.
13. Darestani Farahani T, Entezami AA, Mobedi H, Abtahi M, Degradation of poly(D,L-lactide-co-glycolide) 50:50 implant in aqueous medium, Iran Polym J, 14,753-763, 2005.
14. Cai Z, Wang Y, Zhu LJ, Liu ZQ, Nanocarriers: a general strategy for enhancement of oral bioavail-ability of poorly absorbed or pre-systemically metabolized drugs, Cur Drug Metabol, 11, 197-207, 2010.
15. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang H, Nguyen HN, Hsu CW, Lin KJ, Sung HW, Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma- glutamic acid) nanoparti-cles for oral insulin delivery, Biomaterials, 31, 3384-3394, 2010.
16. Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P, Nanocapsules: a new type of lysoso-motropic carrier, FEBS Lett, 84, 323-326, 1977.
17. Astier A, Doat B, Ferrer MJ, Benoit G, Fleury J, Rolland A, Leverge R, Enhancement of adri-amycin antitumor activity by its binding with an intracellular sustained-release form, poly-methacrylate nanospheres, in U-937 cells, Cancer Res, 48, 1835-1841, 1988.
18. Mu L, Feng SS, A novel controlled release formulation for the anti-cancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS, J Control Rel, 86, 33-48, 2003.
19. Duan Y, Xu S, Wang Q, Liu J, Zhang Z, Optimization of preparation of DHAQ loaded PEG-PLGA-PEG nanoparticlesusing central composite design, J Mater Sci Mater Med, 17, 559-563, 2006.
20. Morgan E, Chemometrics: Experimental Design, John Wiley, London, Ch 5, 1991.
21. Berzas JJ, Rodriguez J, Contento AM, Cabello MP, Determination of drugs used in advanced breast cancer by capillary gas chromatography of pharmaceutical formulation, J Sep Sci, 26, 908-914, 2003.
22. Brigger I, Chaminade P, Marsaud V, Appel M, Besnard M, Gurny R, Renoir M, Couvreur P, Tamoxifen encapsulation within polyethylene glycol-coated nanospheres: a new antiestrogen formulation, Int J Pharm, 214, 37-42, 2001.
23. Chawal JS, Amiji MM, Cellular uptake and concentration of tamoxifen upon administration in poly(D-caprolactone) nanoparticles, AAPS Pharm Sci, 51, 1-7, 2003.
24. Kozak YD, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, Garcia E, Couvreur P, Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis, Eur J Immunol, 34, 3702-3712, 2004.
25. Sehra S, Dhake AS, Formulation and evaluation of sustained release microspheres of poly-lactide-co-glycolide containing tamoxifen citrate, J Microencap, 22, 521-528, 2005.
26. Bempong DK, Monograph development-palmu-nary and steroids, USP29-NF24, (DMPS05), 2057, 2005.
27. Owens DE, Peppas NA, Opsonization, biodistri-bution, and pharmacokinetics of polymeric nanoparticles, Int J Pharm, 307, 93-102, 2006.
28. Kumar CSSR, Biological and Pharmaceutical Nanoparrticles, Wiley-VCH Verlag, Weinheim, 378-385, 2006.
29. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, J Control Rel, 59, 299-307, 1999.
30. Sahana DK, Mittal G, Bhardwaj V, Ravikumar MNV, PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticles formarion and release behavior in vitro and in vivo using stradiol as a model drug, J Pharm Sci, 97, 1530-1542, 2008.
31. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S, Nanocapsule formation by interfacial polymer deposition following solvent displacement, Int J Pharm, R1-R4, 1989.
32. Rafati H, Coombes AGA, Adler J, Holland J, Davis SS, Protein-loaded poly (D,L-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics, J Control Rel, 43, 89-102, 1997.
33. Bourguignon B, Massart DL, Simultaneous optimization of several chromatographic performance goals using Derringer's desirability function, J Chromatogr A, 586, 11-20, 1991.
34. Jimidar M, Bourguignon B, Massart DL, Application of Derringer's desirability function for the selection of optimum separation conditions in capillary zone electrophoresis, J Chromatogr A, 740, 109-117, 1996.